Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Giles

Showing results (541-550 of 610) with videos related to

Pageof 61
Sort By:
Oncogene|January 10, 2019
Correction: Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell deathCharlotte E Johnson, Elaine A Dunlop, Sara Seifan, et al.
Leukemia|March 6, 2013
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinibT D Kim, D Rea, M Schwarz, et al.
Nano Letters|September 17, 2021
Ultrahigh-Resolution, Label-Free Hyperlens Imaging in the Mid-IRMingze He, Ganjigunte R S Iyer, Shaurya Aarav, et al.
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Oncogene|July 8, 2018
Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell deathCharlotte E Johnson, Elaine A Dunlop, Sara Seifan, et al.
Blood Cancer Journal|August 16, 2014
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemiaJ F Seymour, D W Kim, E Rubin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient SurvivalLijie Zhai, Erik Ladomersky, Kristen L Lauing, et al.
Leukemia|July 10, 2012
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemiaF J Giles, R T Swords, A Nagler, et al.
Carcinogenesis|May 27, 2014
Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokersTiffany A Wallace, Ronan F Downey, Caleb J Seufert, et al.
Pageof 61

Showing results (541-550 of 610) with videos related to

Sort By:
Pageof 61
Oncogene|January 10, 2019
Correction: Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell deathCharlotte E Johnson, Elaine A Dunlop, Sara Seifan, et al.
Leukemia|March 6, 2013
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinibT D Kim, D Rea, M Schwarz, et al.
Nano Letters|September 17, 2021
Ultrahigh-Resolution, Label-Free Hyperlens Imaging in the Mid-IRMingze He, Ganjigunte R S Iyer, Shaurya Aarav, et al.
Blood|January 11, 2003
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesStefan Faderl, Deborah A Thomas, Susan O'Brien, et al.
Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Oncogene|July 8, 2018
Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell deathCharlotte E Johnson, Elaine A Dunlop, Sara Seifan, et al.
Blood Cancer Journal|August 16, 2014
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemiaJ F Seymour, D W Kim, E Rubin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient SurvivalLijie Zhai, Erik Ladomersky, Kristen L Lauing, et al.
Leukemia|July 10, 2012
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemiaF J Giles, R T Swords, A Nagler, et al.
Carcinogenesis|May 27, 2014
Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokersTiffany A Wallace, Ronan F Downey, Caleb J Seufert, et al.
Pageof 61